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Abstract
Background and Aim: A neuronal pathway participates in the development of portal hypertension: blockade of afferent
sensory nerves in portal vein ligated (PVL) rats simultaneously prevents brain cardiovascular regularory nuclei activation,
neuromodulator overexpression in superior mesenteric ganglia, sympathetic atrophy of mesenteric innervation and
hemodynamic alterations. Here we investigated in PVL rats alterations in neuromodulators and signaling pathways leading
to axonal regression or apoptosis in the superior mesenteric ganglia and tested the effects of the stimulation of neuronal
proliferation/survival by using a tyrosine kinase receptor A agonist, gambogic amide.
Results: The neuronal pathway was confirmed by an increased neuronal afferent activity at the vagal nodose ganglia and
the presence of semaphorin3A in sympathetic pre-ganglionic neurons at the intermediolateral nucleus of the spinal cord of
PVL rats. Expression of the active form of tyrosine kinase receptor A (phosphorylated), leading to proliferation and survival
signaling, showed a significant reduction in PVL comparing to sham rats. In contrast, the apoptotic and axonal retraction
pathways were stimulated in PVL, demonstrated by a significant overexpression of semaphorin 3A and its receptor
neuropilin1, together with increases of cleaved caspase7, inactive poly(ADP-ribose) polymerase and Rho kinase expression.
Finally, the administration of gambogic amide in PVL rats showed an amelioration of hemodynamic alterations and
sympathetic atrophy, through the activation of survival pathways together with the inhibition of apoptotic cascades and
Rho kinase mediated axonal regression.
Conclusion: The adrenergic alteration and sympathetic atrophy in mesenteric vessels during portal hypertension is caused
by alterations on neuromodulation leading to post-ganglionic sympathetic regression and apoptosis and contributing to
splanchnic vasodilation.
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Introduction
The hemodynamic alteration of portal hypertension in patients
with liver cirrhosis contributes to most of the clinical manifesta-
tions of the disease: gastrointestinal bleeding, hepatic encephalop-
athy, ascites and renal failure. In the physiopathology of this
vascular alteration, splanchnic vasodilation plays an essential role
in initiating the hemodynamic process. Regardless of the
extensively demonstrated humoral factors involved in splanchnic
vasodilatation [1,2], we have previously shown a remarkable local
alteration of the mesenteric adrenergic system (inhibition of
adrenergic genes and proteins and atrophy of sympathetic
structures), as a possible contributory factor to splanchnic arterial
vasodilation [3,4]. It has also been proposed that during portal
hypertension, pressure changes detected at portal level could be
the afferent sensory signal triggering this hemodynamic response
[5]. We have demonstrated that blockade of sensory afferent
nerves in portal hypertensive rats, simultaneously prevents c-fos
activation in cardiovascular regulatory nuclei of the brain,
hemodynamic alterations and sympathetic atrophy of nerves
innervating the superior mesenteric artery (SMA) [6–8].
Considering this neuronal pathway, the signal responsible for
the post-ganglionic sympathetic atrophy could be originated in
pre-ganglionic fibers that synapse at the superior mesenteric
ganglion (SMG). By analyzing the SMG of portal vein ligated
(PVL) rats, we have shown an overexpression of nerve growth
factor (NGF) and its precursor (proNGF), as well as an increase in
the neurotrophin receptor p75 (p75NTR) and in the chemor-
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epellent molecule semaphorine 3A (Sema3A) [6]. This altered
neuromodulator expression in the SMG of PVL rats suggested that
the adrenergic downregulation and sympathetic atrophy observed
in mesenteric vessels might have their origin in disorders leading to
axonal regression and/or apoptosis. Interplaying signaling path-
ways are responsible for the modulation of axonal survival and
death (figure 1). While NGF is a neurotrophin responsible for
neuronal survival and growth, its precursor pro-NGF can directly
induce neuronal regression/death, when its effect is mediated by
p75NTR [9,10] or indirectly through the inhibition of tyrosine
kinase receptor A (TrkA) NGF-mediated activation [11]. Sema3A
strongly inhibits axonal growth in situations of intense NGF
stimulation, by dephosphorylating the NGF main neuronal
receptor TrkA [12]. In turn, when active, TrkA promotes
neuronal survival through the silencing of the apoptotic signal
mediated by p75NTR [13]. Finally, neurotrophin binding to
p75NTR is necessary for Sema3A-mediated axonal regression/
growth cone collapse [14,15].
This study was aimed to (i) confirm the implication of the
neuronal pathway in portal hypertension by analyzing two
intermediate structures: the nodose ganglia in the afferent
direction, containing the neuronal soma of afferent sensitive
nerves running along the vagus nerve and the intermediolateral
nucleus of the spinal cord in the efferent direction, containing the
neuronal bodies of pre-ganglionic sympathetic nerves; (ii) further
explore the neuromodulators and signaling pathways that, in the
SMG of PVL rats, lead to Sema3A/ProNGF/p75NTR-mediated
axonal regression or apoptosis; and (iii) find out whether treatment
of PVL rats with gambogic amide, a TrkA agonist, inhibits this
neurodegenerative pathway, and consequently, the hemodynamic




Animals received humane care and all efforts were made to
minimize suffering, according to the recommendations of the
European Commission on the protection of animals used for
experimental and scientific purposes (http://ec.europa.eu/
environment/chemicals/labanimals/pdf/report_ewg.pdf). All an-
imal experiments were approved by The Animal Care Committee
of the Vall d’Hebron Institut de Recerca (VHIR), Barcelona,
Spain (Associate permit number:5953).
Experimental portal hypertension
Prehepatic portal hypertension was induced by partial portal
vein ligation as described previously [3]. Two groups of 7 portal
hypertensive rats and 7 sham operated rats were studied. A third
group of 16 PVL animals were treated daily with gambogic amide
Figure 1. Interplaying signaling pathways responsible for the modulation of axonal survival and death. NGF, nerve growth factor;
proNGF, NGF precursor; TrkA, tyrosine kinase receptor A, p75NTR, neurotrophin receptor p75; Sema3A, semaphorin 3A; JNK, c-Jun N-terminal kinase;
RhoA, Ras homolog family member A; ROCK, Rho kinase; MAPK/ERK, mitogen activated protein kinase; AKT, protein kinase B; nNOS, neuronal nitric
oxide synthase; NO, nitric oxide; Casp-7, cleaved caspase 7; PARP, poly(ADP-ribose) polymerase.
doi:10.1371/journal.pone.0084374.g001
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(n = 8) (Enzo, Farmingdale, NY, USA) or vehicle (1% DMSO)
(n = 8), beginning the same day of the PVL surgery and during 14
days. Gambogic amide was intreperitoneally (i.p.) injected at
0.35 mg/kg body weight (BW). In order to have normal state
reference values, 8 sham rats were also performed.
Hemodynamic measurements
Two weeks after PVL surgery or sham operation, animals were
anaesthetized with a mix of ketamine hydrochloride (100 mg/kg
BW, i.p.) plus midazolam (5 mg/kg BW, i.p.) for continuous
measurement of mean arterial pressure (MAP, mmHg), portal
pressure (PP, mmHg) and SMA blood flow (SMABF, ml/
min.100 g). SMA resistance (SMAR, mmHg/ml.min.100 g) was
calculated as (MAP-PP)/SMABF.
Sample extraction
See data S1 for details.
Antibodies for Western blot analysis
Protein expression analysis was performed in nodose ganglion
samples for calcitonin gene related protein (CGRP) (diluted 1/500)
(Biomol, Pennsylvania PA, USA) and in SMG for tyrosine
hydroxylase (Th) (dil 1/600), Sema 3A, sortilin (Sort1) (diluted
1/1000) (Abcam, Cambridge, UK), TrkA, Rho kinase (ROCK)
(diluted 1/200) (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), phospho-TrkA (pTrkA), mitogen activated protein kinase
(MAPK), phospho-MAPK (pMAPK), c-Jun N-terminal kinase
(JNK), phospho-JNK (pJNK), protein kinase B (AKT), phospho-
AKT (pAKT), cleaved caspase7 (casp-7), poly(ADP-ribose) poly-
merase (PARP) (diluted 1/1000) (Cell Signaling Technology,
Beverly, MA, USA) and neural nitric oxide synthase (nNOS) (1/
1000) (BD Biosciences, San Jose, CA, USA). See data S1 for
details.
Immunofluorescence
Serial 8 mm sections of spinal cord were analyzed for vesicular
acetylcholine transporter (VAChT, diluted 1:200) (Novus Biolog-
icals, Littleton, CO, USA) immunoreactivity, as a marker of
preganglionic sympathetic cholinergic neurons. Successive slides
were used to analyze Sema3A immunoreactivity(diluted 1:200).
Bound antibodies were incubated with anti-goat IgG DyLight 594
(diluted 1:500) (Bethyl, Montgomery, TX, USA) for VAChT and
with anti-rabbit-FITC (diluted 1/500) (Abcam, Cambridge, UK)
for Sema3A
Paraffin-embedded sections of SMG were incubated with
primary antibodies neuropilin-1 (Nrp-1) (R&D Systems, Minne-
apolis, MN, USA) (diluted 1:20), p75NTR (diluted 1/500) (Abcam),
Sort-1 (diluted 1/200) and TrkA (diluted 1/200). Bound antibod-
ies were incubated with anti-rabbit-FITC. See data S1 for details.
Immunohistochemistry
Total nervous area and Th staining area was carried out by
immunohistochemistry on paraffin-embedded sections of SMA
incubated with primary antibody anti-Th (diluted 1:250) as
described [4,8].
Statistical analysis
Normally distributed values were compared using Student’s t-
test and expressed as mean 6 S.E.M. Statistical significance was
established at p,0.05.
Results
The afferent signal through the vagus nerve is increased
in portal hypertension
Visceral afferent sensitive nerves release the neurotransmitter
CGRP upon stimulation, not only from the terminals of primary
afferent fibers, but also from the cell bodies and along axons.
CGRP expression was analyzed in the nodose ganglia containing
the neuronal soma of afferent sensitive nerves running along the
vagus nerve. The result clearly showed a significant 4-fold increase
of CGRP expression in PVL rats compared to sham (p,0.001)
(figure 2).
Expression of semaphorin 3A in pre-ganglionic
cholinergic neurons
In a previous study, Sema3A overexpression was localized at the
cholinergic axon fibers surrounding adrenergic neurons in the
SMG (8). We hypothesized a cholinergic pre-ganglionic origin for
this increase in Sema3A and searched for its presence in the
intermediolateral nucleus of the spinal cord (spinal segments from
T9 to T13) containing the cell bodies of preganglionic sympathetic
neurons that synapse at the SMG. As shown in figure 3,
cholinergic VAChT inmunoreactive neurons were present in the
ventral horn (figure 3A) and in the intermediolateral nucleus
(figure 3B) of the spinal cord. As expected, the size and staining
pattern were different between neurons from both locations, being
smaller and uniformly stained neurons at the intermediolateral
nucleus, without the punctuated appearance of the cholinergic
neurons at the ventral horn. In successive sections, positive
Sema3A immunofluorescent signal was only found in neurons
located at the intermediolateral nucleus of the spinal cord of PVL
rats, showing a similar size and staining pattern as cholinergic
neurons (figure 3B).
Figure 2. Calcitonin gene related protein (CGRP) in the nodose
ganglion. Bar diagram showing CGRP quantitation by Western blot
analysis in sham (n = 6) and PVL (n = 7). Representative Western blot is
shown below.
doi:10.1371/journal.pone.0084374.g002
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Tyrosine hidroxylase deficit and semaphorine 3A/
neuropilin 1 overexpression in adrenergic neurons of the
superior mesenteric ganglion in PVL rats
In order to confirm the adrenergic deficit previously found in
mesenteric arteries of PVL rats [4,6], Th expression was analyzed
by Western blot in the SMG of PVL and sham rats. A significant
70% decreased in Th expression was found in PVL animals
(p = 0.008) (figure 4A). The increased expression of Sema3A in the
SMG of PVL, already demonstrated in a previous work [6], was
confirmed by Westen blot analysis in PVL animals compared to
sham (p,0,001) (figure 4A). Moreover, immunofluorescent
analysis showed that Sema3A receptor Nrp1, located at the
cytoplasm of adrenergic neurons of the SMG, was significantly
overexpressed in SMG neurons of PVL animals compared to
sham (p = 0.003) (fig 4B and C). Finally, immunodetection of
p75NTR, Sort1 and TrkA demonstrated their presence in the
cytoplasm of adrenergic neurons in the SMG (figure S1).
Moreover, co-localization of p75 NTR and Sort1 was observed
(figure S2).
The axonal retraction/apoptotic pathways are activated
in the superior mesenteric ganglion from PVL rats
Expressions of different proteins involved in the signaling
pathways activated by either pro-NGF/NGF or Sema 3A were
studied (figure 1). TrkA is the specific receptor for NGF and its
activation leads to proliferative and prosurvival signaling through
MAPK/AKT pathways. Although TrkA expression was not
different between sham and PVL rats (not shown), its activated
form, pTrkA, was decreased in PVL animals showing a decreased
pTrkA/TrkA ratio in PVL rats compared to sham (p = 0.015)
(figure 5). However, MAPK and AKT ratios showed no
differences between PVL and sham groups (figures 1 and 5). In
contrast, the apoptotic and axonal retraction pathways, activated
by pro-NGF-p75NTR and Sema3A-Nrp1, respectively, showed
changes in PVL rats. On the one hand, the apoptotic cascade
seemed to be activated in PVL compared to sham, demonstrated
by strong increments in cleaved forms of Casp7 (25 and 20 kD)
(p,0.001) and in the inactive form of PARP (p = 0.001). On the
other hand, we were unable to find differences in JNK (not shown)
or pJNK expression between PVL and sham rats (figure 5). Finally,
our results demonstrated that ROCK expression, which regulates
axonal retraction in response to Sema3A signaling, was largely
increased (.3-fold) in PVL rats compared to sham (p = 0.03)
(figures 1 and 5).
Gambogic amide improves hemodynamic alterations
and sympathetic atrophy in PVL rats
PVL animals treated with vehicle exhibited the characteristic
hemodynamic changes observed in this model of portal hyperten-
sion (table 1). In contrast, PVL animals treated with gambogic
amide (PVL-GA) improved hemodynamic parameters, except for
PP, being significantly different from PVL vehicle. Although not
achieving normal state sham values (shown in table 1 as a
reference) PVL-GA animals presented a distinct intermediate
hemodynamic state.
Analysis of the total nervous area surrounding the outer part of
the arterial wall in SMA sections and the Th staining area within
these nervous structures showed that both parameters were
significantly lower in PVL vehicle than PVL-GA. Gambogic
amide treated animals revealed less nerve atrophy demonstrated
by a significant increase in total SMA nervous area (p = 0.03).
Regarding the Th expressing area within the nervous structures
PVL-GA animals also showed a significant increment compared to
PVL vehicle (p = 0.04) (figure 6).
Axonal regression/apoptosis within the superior
mesenteric ganglia is decreased in PVL rats treated with
gambogic amide
Administration of the TrkA agonist, gambogic amide, to PVL
rats also changed the expression of most proteins implicated in
neuronal growth/apoptosis pathways (figure 1). First of all, PVL-
GA animals showed a significant increase in TrkA and pTrkA
Figure 3. Semaphorin 3A (Sema3A) in the intermedioratelal nucleus of the spinal cord in PVL rats. (A) Magnifications (4006) of the
ventral horn area of the spinal cord (middle gray color image at 46), containing cholinergic neurons, showing strong VAChT immunofluorescent
signal and null immunoreactivity for Sema3A. (B) Magnifications (4006) of the spinal cord intermediolateral nucleus containing cholinergic
preganglionic sympathetic neurons. These neurons show positive immunofluorescent signal for both VAChT and Sema3A. HE, hematoxilin-eosin
staining.
doi:10.1371/journal.pone.0084374.g003
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compared to PVL vehicle (p = 0.04 and p = 0,012, respectively).
Consequently, pMAPK/MAPK and pAKT/AKT ratios were also
significantly increased in PVL-GA compared to PVL vehicle
animals (figure 7). This increased pAKT/AKT ratio suggested
that it might be interesting to study the expression of nNOS, since
it is the main source of NO in this tissue. As shown in figure 7,
there was a significant 62% increase in nNOS expression in PVL-
GA with respect to PVL vehicle rats (p = 0.008). On the other
hand, compared with PVL vehicle, ROCK expression was
significantly diminished in PVL-GA (p,0.001). Although cleaved
Casp7 expression presented a slight non significant decrease in
PVL-GA compared to PVL vehicle, the expression of cleaved
PARP showed a significant decrease in PVL animals (p = 0,04)
(figures 1 and 7).
Discussion
Based on previous studies, we have hypothesized that the
observed post-ganglionic sympathetic nerve regression in the
splanchnic area would lead to neurotransmission inhibition and
vasoconstriction impairment and constitute an additional contrib-
utory factor to arterial splanchnic vasodilation of portal hyper-
tension [3,4,6]. This sympathetic nerve regression could be the
result of efferent sympathetic signals synapsing at the SMG level.
The origin of this neural response being an afferent signal, coming
from portal or mesenteric pressure increments and reaching the
brain stem cardiovascular nuclei through the vagus nerve [5,7,8].
The results of the present study support our hypothesis and
demonstrate that an altered neuromodulator expression at the
level of mesenteric sympathetic ganglia, leading to sympathetic
axonal regression and apoptosis, is implicated in the development
of splanchnic vasodilation. By pharmacological manipulation, the
neuromodulation profile can be improved, the sympathetic
atrophy ameliorated and the hemodynamic alteration of portal
hypertension partially reverted.
The neural signaling in portal hypertension
In this work, we have first analyzed two intermediate structures
of this neural routing, the nodose ganglia in the afferent direction
and the intermediolateral nucleus of the spinal cord in the efferent
direction. The increased expression of the neuropeptide CGRP in
the nodose ganglia of PVL rats, containing afferent capsaicin
sensitive neurons, confirms an enhanced afferent signal through
the vagus nerve in portal hypertension (figure S3). In this sense, it
has been recently shown that capsaicin vagal denervation
completely blocks this increased sensitive signal and abrogates
hyperdynamic circulation in PVL rats [7]. In the efferent
direction, VAChT immunostaining enabled localization of cell
bodies of pre-ganglionic neurons at the intermediolateral nucleus
of the spinal cord (segments from T9 to T13) that synapse later
with post-ganglionic sympathetic neurons in the SMG. Further-
more, Sema3A positive immunostaining of these neurons
supported the origin of Sema3A overexpression observed previ-
ously at the SMG of PVL in these cholinergic pre-ganglionic fibers
[6]. Therefore, the efferent signal coming from the brain
cardiovascular nuclei may induce the pre-ganglionic sympathetic
neurons at the intermediolateral nucleus to produce Sema3A.
From there, Sema3A could travel and be secreted at the SMG,
affectting post-ganglionic adrenergic neurons and leading to axon
growth inhibition, retraction or death [16–18] (figure S3). It is well
known that the development of hyperdynamic splanchnic circu-
lation in portal hypertensive rats is an angiogenesis-dependent
process that can be markedly inhibited by blockade of the VEGF
signaling pathway [19,20]. The increase in Sema3A might also be
necessary to redirect axons to innervate newly formed blood
vessels from preexisting vasculature during portal hypertension
[21]. In this process, activation of neuronal death or axonal
retraction might be a collateral damage of the increased Sema3A
levels.
Altered neuromodulator expression in superior
mesenteric ganglia
Data from the present study expands and completes our
previous results [6] on the exploration of neuronal markers in the
SMG and its signaling pathways in portal hypertension. First of all,
we verified the adrenergic deficit previously observed in mesen-
teric arteries, in the SMG of PVL rats [3,4,6] through the analysis
of Th expression, a well-accepted marker of sympathetic activity.
Increased expression of Sema3A and its receptor Nrp1 were also
Figure 4. Tyrosine hydroxylase (Th), semaphorine 3A (Sema3A)
and neuropilin (Nrp1) in the superior mesenteric ganglion
(SMG). (A) Bar diagrams showing Th and Sema 3A quantitation by
Western blot analysis in sham (n = 6) and PVL (n = 7). Representative
Western blots are shown below. (B) Representative images of Nrp1
immunoreactivity in sections of SMG at 4006from sham (n = 6) and PVL
(n = 5). (C) Quantitation of intensity density of Nrp1 fluorescence in each
experimental group.
doi:10.1371/journal.pone.0084374.g004
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confirmed in the SMG of PVL rats. Moreover, to rule out the
possibility that Sema3A, NGF or proNGF could be acting on
different cells other than adrenergic neurons of the SMG, we
analyzed the expression of receptors Nrp1, TrkA, p75NTR and
Sort1 by immunofluorescence and found that they only localized
in the cytoplasm of adrenergic neurons. These results reinforce the
idea that an altered activity in the sympathetic neurons of the
SMG is in the origin of mesenteric sympathetic atrophy.
TrkA and p75NTR are mature NGF coreceptors, wherein TrkA
transduces survival and differenciative signaling and p75NTRmo-
dulates the affinity and selectivity of TrkA activation (9) (figure 1).
On the other hand, proNGF engages p75NTR and sortilin to
iniciate p75NTR –dependent apoptotic cascade [22,23] or to
activate, in partnership with Sema3A, the signaling pathway
leading to growth cone collapse and axonal retraction [15]. In
turn, Sema3A is a negative regulator of NGF-induced neurite
outgrowth via de-phosphorylation of TrkA, independently of its
growth cone repulsion activity [12] (figure 1). Our data pointed
out to the activation of p75NTR inducing axonal regression and
apoptosis and to the inactivation of TrkA by Sema3A. Although
TrkA expression did not change in portal hypertensive animals,
our results showed a diminished expression of its active
phosphorylated form. This was predictable as the observed
overexpression in Sema3A could be acting on TrkA de-
phosphorylation of residues Tyr490 and Tyr785 (SCH and PLCc
docking sites, respectively) [12,24]. Surprisingly, we were no able
to find differences in the downstream signaling cascade regulated
by these two tyrosine residues; levels of MAPK or its active
phosphorylated form showed no difference between sham and
PVL rats. We don’t have an exact explanation for this result but
our in vivo tissue-type analysis cannot discriminate between the
expression of MAPK originated only from NGF-TrkA stimulation
in adrenergic neurons and from the many other sources of MAPK
activation [25].
On the contrary, the signaling pathways activated by proNGF/
Sema3A leading to neuronal apoptosis and axonal regression were
markedly activated in PVL animals. Sema3A repulsive guidance
signaling converges upon ROCK which propagates this signal
down to the cytoskeleton acting as a key mediator of neuron
growth inhibition and axon retraction [26] (figure 1). Moreover,
Figure 5. Expression of proteins involved in axonal survival and death pathways in the superior mesenteric ganglion. Bar diagrams
showing quantitation by Western blot of (A) the ratio of phosphorylated and total forms of tyrosine kinase receptor A (TrkA), mitogen activated
protein kinase (MAPK), protein kinase B (AKT) and (B) c-Jun N-terminal kinase (JNK), cleaved caspase 7 (Casp-7), poly(ADP-ribose)polymerase (PARP)
and Rho kinase (ROCK), in sham (n = 7) and PVL (n = 7). Representative Western blots are shown below. Only bands corresponding to the
phosphorylated form are exemplified in the case of the quantitation of ratios. Grouping of bands from different parts of the same gel are denoted by
dividing lines.
doi:10.1371/journal.pone.0084374.g005
Table 1. Analysis of hemodynamic measurements of sham and PVL rats after gambogic amide or vehicle administration.
PP (mmHg) MAP (mmHg) SMABF (ml/min.100 g) SMAR (mmHg/ml.min.100 g
Sham (n = 8) 10,260,2 121,962,0 4,460,4 26,962,4
PVL V (n = 8) 15,760,4 97,462,7 7,260,5 11,760,9
PVL GA (n = 8) 14,660,8 111,664,6 * 5,860,39 * 16,360,6 **
*p,0.05, ** p,0.001 compared with PVL V.
doi:10.1371/journal.pone.0084374.t001
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caspases have been shown to irreversibly activate ROCK by
truncation and generation of a constitutively active form [27]. Our
results showed that the caspase cascade is activated in PVL rats
demonstrated by important increments in cleaved Casp7 expres-
sion and in the inactive form of PARP; this caspase activation
might be unrelated to the JNK pathway signaling. Simultaneously,
the increased ROCK expression points out to an activated process
of axon retraction in portal hypertension, either from Sema3A
signaling or from caspase-dependent apoptosis.
Figure 6. Analysis of sympathetic atrophy in the superior mesenteric artery (SMA) after gambogic amide administration. (A)
Representative images of tyrosine hydroxylase (Th) immunostaining at 406 showing transversal sections of complete arterial wall (AW) surrounded
by nervous structures from sham (showed as a normal state reference), PVL vehicle (PVL-V) (n = 6), PVL gambogic amide (PVL-GA) (n = 6), *p,0.05,
**p,0.001, compared to PVL-V. (B) Bar diagrams showing immunohistochemical quantitation of total nervous area and Th staining area in nerves
surrounding the SMA from experimental groups PVL-V and PVL-GA.
doi:10.1371/journal.pone.0084374.g006
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Treatment with gambogic amide
In the last part of this study, we tested the hypothesis that by
manipulating this altered survival/death neuromodulator path-
ways, substantial changes in sympathetic atrophy and splanchnic
vasodilation would be observed. We have tested gambogic amide,
a small-molecule agonist for TrkA receptor, to reverse or modify
TrkA altered expression or the intermediary molecules in its
signaling pathway [28]. The selective interaction of gambogic
amide with the cytoplasmic juxtamembrane domain of TrkA
triggers the phosphorylation of TrkA at tyrosine residues Y490
and Y751, elicits AKT and MAPK activation and prevents
neuronal cell death [28]. The results obtained from the analysis of
proteins involved in growth and death neuronal pathways in the
SMG agree with the observed improvement of the sympathetic
atrophy in the nervous fibers surrounding the SMA of treated PVL
rats. As a primary effect, gambogic amide significantly induces the
activation of TrkA, consequently increasing AKT and MAPK
expression above the expression levels found in PVL vehicles. This
increase in neuronal growth and proliferation, by itself, could be
counteracting the neurodegenerative process demonstrated in the
SMG of PVL rats. Moreover, the dramatic decrease in ROCK
and PARP content of PVL rats treated with gambogic amide,
suggests that the activation of the AKT survival pathway promotes
not only inhibition of axon retraction via ROCK, but also
blockade of the caspase cascade leading to apoptosis. To this
inhibition might also contribute the overexpressed nNOS by the
generation of nitric oxide (figure 1) [29,30].
Our results showed that the hemodynamic alteration and
sympathetic atrophy are simultaneously improved in PVL rats
treated with gambogic amide. We believe that the improvement in
Figure 7. Protein expression in the superior mesenteric ganglion after gambogic amide administration. Bar diagrams showing
quantitation by Western blot analysis of (A) tyrosine kinase receptor A (TrkA), phospho-TrkA (pTrkA), (B) the ratio of phosphorylated and total forms
of mitogen activated protein kinase (MAPK) and protein kinase B (AKT) and neuronal nitric oxide synthase (nNOS), (C) Rho kinase (ROCK), cleaved
caspase 7 (Casp-7) and poly(ADP-ribose)polymerase (PARP) in PVL treated with vehicle (PVL-V) (n = 8) or gambogic amide (PVL-GA) (n = 8).
Representative Western blots are shown below. Only bands corresponding to the phosphorylated form are exemplified in the case of the
quantitation of ratios. Grouping of bands from different parts of the same gel are denoted by dividing lines.
doi:10.1371/journal.pone.0084374.g007
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hemodynamic parameters is mostly due to the prevention of
sympathetic atrophy. An increase in both sympathetic nervous
area and tyrosine hydroxylase expression in PVL-GA probably
contribute to restore a normal state of vasoconstriction. However,
the hemodynamic improvement is not complete, because PVL-GA
rats do not show the hemodynamic parameters of healthy
individuals. The main reason for this incomplete improvement is
that sympathetic atrophy only partially explains mesenteric
vasodilation since other factors certainly intervene in this
alteration. Another possible explanation to the lack of a complete
hemodynamic/nervous restoration could come from the possible
opposed effects of gambogic amide in different tissues in the
mesenteric territory. Activation of TrkA in the SMG can promote
the proliferation and survival of sympathetic nerve structures,
followed by a consequent increment on adrenergic neurotrans-
mission and eventually vasoconstriction. On the other hand,
gambogic amide could be inducing at the same time SMA
vasodilation via an increased phosphorylation of TrkA, AKT and
eNOS.
In summary, during portal hypertension splanchnic arterial
vasodilation is accompanied by sympathetic nerve atrophy. This
sympathetic nerve regression is caused by a simultaneous
inhibition of neuronal growth/survival pathways and the stimu-
lation of neuronal apoptosis and axonal retraction processes, at the
level of ganglionic sympathetic neurons. Reverting this altered
neuromodulator alteration with a TrkA receptor agonist, partially
prevents mesenteric sympathetic regression and improves the
hemodynamic alteration of portal hypertension, indicating that
sympathetic nerve regression is a contributory factor to splanchnic
vasodilation in portal hypetension.
Supporting Information
Figure S1 Immunofluorescent detection of tyrosine
kinase receptor A (TrkA), neurotrophin receptor p75
(p75NTR) and sortilin 1 (Sort1) in the sympathetic
adrenergic neurones of the superior mesenteric gangli-
on.
(TIF)
Figure S2 Immunofluorescent co-localization of sortilin
1 (Sort1) and neurotrophin receptor p75 (p75NTR) in
sympathetic adrenergic neurons of the superior mesen-
teric ganglion.
(TIF)
Figure S3 The neural pathway in portal hypertension.
NE: norepinephrine.
(TIF)
Data S1 Data Supplement
(DOC)
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